Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 + Pembrolizumab in HA-High NSCLC and Gastric Cancer
NCT02563548Phase 1Completed
- Sponsor
- Halozyme Therapeutics, Inc.
- Start
- Oct 2015
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegvorhyaluronidase alfa in non-small cell lung cancer (NSCLC) and gastric adenocarcinoma (2 arms), sponsored by Halozyme Therapeutics, Inc. Primary endpoints: Number of Participants With Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With Pembrolizumab and 2 more. Started Oct 2015; status: completed.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
non-small cell lung cancer (NSCLC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT02563548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563548.